Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $57.75 USD
Change Today +0.15 / 0.26%
Volume 8.5M
MRK On Other Exchanges
Symbol
Exchange
New York
Mexico
EN Paris
Sao Paulo
Frankfurt
As of 8:04 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

merck & co. inc. (MRK) Snapshot

Open
$57.83
Previous Close
$57.60
Day High
$58.23
Day Low
$57.63
52 Week High
01/13/15 - $63.62
52 Week Low
10/16/14 - $52.49
Market Cap
163.9B
Average Volume 10 Days
13.4M
EPS TTM
$2.01
Shares Outstanding
2.8B
EX-Date
03/12/15
P/E TM
28.7x
Dividend
$1.80
Dividend Yield
3.08%
Current Stock Chart for MERCK & CO. INC. (MRK)

merck & co. inc. (MRK) Details

Merck & Co., Inc. provides health care solutions worldwide. The company offer therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal infections, intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, male pattern hair loss, and fertility diseases. It also offers neuromuscular blocking agents for use in surgery; anti-bacterial products for skin and skin structure infections; antidepressants; ophthalmic and cholesterol modification products; non-sedating antihistamine; and vaginal contraceptive implants. In addition, the company provides products to prevent chemotherapy-induced and post-operative nausea and vomiting; to treat brain tumors and melanoma; to prevent diseases caused by human papillomavirus, as well as vaccines for measles, mumps, rubella, varicella, chickenpox, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it offers animal health products, including antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics for, and vaccines against bacterial and viral disease in fish. Additionally, the company provides companion animal products, such as diabetes mellitus treatment drugs and vaccines for dogs and cats; ointments for acute and chronic otitis; anthelmintic products; chewable tablets to kill fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. The company serves drug wholesalers and retailers, hospitals, government entities and agencies, physicians, physician distributors, veterinarians, distributors, and animal producers, as well as managed health care providers. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.

70,000 Employees
Last Reported Date: 02/27/15
Founded in 1891

merck & co. inc. (MRK) Top Compensated Officers

Chairman, Chief Executive Officer and Preside...
Total Annual Compensation: $1.5M
Executive Vice President and President of Mer...
Total Annual Compensation: $1.2M
President of Global Human Health and Executiv...
Total Annual Compensation: $957.3K
Compensation as of Fiscal Year 2013.

merck & co. inc. (MRK) Key Developments

Ablynx Extends its Initial Two-Year Research Collaboration with Merck & Co. Inc

Ablynx announced an extension of its initial two-year research collaboration with Merck & Co. Inc. to develop and commercialise Nanobody candidates directed towards an undisclosed voltage gated ion channel. Ablynx announced that Merck & Co will extend their funding of the research collaboration with Ablynx to the end of September 2016. This ion channel collaboration was announced in October 2012 and included a EUR 6.5 million upfront payment and EUR 2 million in initial research funding. Merck and Ablynx have a separate collaboration in the field of cancer immuno-therapy, announced in February in 2014, with a EUR 20 million upfront payment, EUR 10.7 million in research funding and total potential milestone payments of up to EUR 1.7 billion plus royalties. In addition, Ablynx is eligible to receive research funding and up to EUR 448 million in research, regulatory and commercial milestone payments associated with the progress of multiple candidates, as well as tiered royalties on any products derived from the collaboration. Ablynx is responsible for the discovery of Nanobody candidates and Merck is responsible for the research, development, manufacturing and commercialisation of any Nanobody product resulting from the collaboration.

Merck Announces New Data Evaluating KEYTRUDA to be Present in Clinical Trials Plenary Session at AACR 2015

Merck announced that new data evaluating KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, in both advanced non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma will be presented as part of the Clinical Trials Plenary Session on Sunday, April 19 at the American Association for Cancer Research (AACR) Annual Meeting in Philadelphia, April 18 " 22. The NSCLC data will be the first presentation of new efficacy and safety findings for KEYTRUDA from 495 patients, including validation of PD-L1 expression (abstract #CT104). These data are from the largest, multi-center Phase 1b (KEYNOTE-001) study of an anti-PD-1 therapy. With the mesothelioma findings (abstract #CT103), data evaluating KEYTRUDA will have been presented in eight different types of cancer.

Hagens Berman Files Wrongful Death Lawsuit Against Merck & Co. Inc. for Suicide Allegedly Linked to Hair Loss Drug Propecia

Hagens Berman represented surviving family members in a wrongful death lawsuit against Merck & Co. for allegedly failing to warn of dangerous side effects relating to suicidality and suicide ideation in its prescription hair loss drug Propecia. Hagens Berman is seeking information from others who have taken Propecia and experienced these side effects. The first-of-its-kind lawsuit filed on Mar. 5, 2015, in the U.S. District Court for the Southern District of California, by the surviving spouse and two children of decedent John Pfaff, alleges that Propecia has known risks of depression and suicidal ideation, behavior and risk, but since the drug's inception in 1997 through 2010, Merck never included a warning about either risk on the Propecia label or in literature distributed with the drug. Merck eventually added depression to the drug's warning label in late 2010, but still, to this day, fails to warn of the risks of suicidal ideation and increased suicidal behavior. The lawsuit states that Merck omitted these risks, despite reports of depression and suicide ideation in clinical studies. Suicide ideation means thinking about, considering, or planning for suicide by the Centers for Disease Control and Prevention. The Pfaff family lost a father and husband when John Pfaff took his own life. John was prescribed Propecia by his dermatologist in May 2008 and spiraled into a deep depression followed by suicide ideation that lingered even after he stopped taking the drug in 2012, the suit states. The Propecia-induced depression was followed by suicide ideation, and eventually, John took his own life. Because of Defendant Merck's strict negligence and breach of express and implied warranties in failing to warn of these dangerous side effects, they are liable for the injury to and wrongful death of John D. Pfaff, the complaint states. The lawsuit seeks wrongful death and survival action damages against Merck on behalf of John's surviving family. Merck promoted the use of Propecia for treatment of male pattern hair loss as safe for its intended use even though Merck knew or should have known about these dangerous side effects and failed to warn users.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MRK:US $57.75 USD +0.15

MRK Competitors

Market data is delayed at least 15 minutes.

Company Last Change
3M Co $163.50 USD +0.91
Bayer AG €139.61 EUR +0.422
Gilead Sciences Inc $101.00 USD -0.075
Pfizer Inc $34.53 USD +0.37
Sanofi €91.69 EUR +0.31
View Industry Companies
 

Industry Analysis

MRK

Industry Average

Valuation MRK Industry Range
Price/Earnings 14.1x
Price/Sales 3.9x
Price/Book 3.4x
Price/Cash Flow 13.7x
TEV/Sales 3.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MERCK & CO. INC., please visit www.merck.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.